Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Esophagus Cancer
NCT03542422Phase 2Unknown
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Jun 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03542422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542422.